Johnson & Johnson Shares Rise On Q1 Profit And Revenue Beat And Raised Guidance -- MarketWatch

Dow Jones

15 Apr

Johnson & Johnson $(JNJ)$ shares rose 0.4% in premarket trades after the medical-technology and drug company beat Wall Street's profit and revenue estimates and raised its full-year sales guidance.

Johnson & Johnson reported per-share earnings of $4.54 for the quarter, which includes the reversal of special charges, up from $1.34 a share in the prior year's quarter.

Adjusted for one-time items, EPS came to $2.77 a share, above the $2.58 FactSet consensus.

Sales rose 2.4% to $21.893 billion, above the FactSet consensus of $21.559 billion. The New Brunswick, N.J.-based company raised its full-year operational sales guidance to a range of $91.6 billion to $92.4 billion, from its prior outlook of $90.9 billion to $91.7 billion. Johnson & Johnson said that this reflects the addition of the CAPLYTA medication for treating bi-polar depression following the completion of the Intra-Cellular Therapies acquisition.

In a separate announcement, Johnson & Johnson announced a 4.8% increase in its quarterly dividend, from $1.24 to $1.30 a share. The raised marked the 63rd year of consecutive dividend raises, the company said.

(This is a developing news story with updates to come.)

-James Rogers

For more from MarketWatch: http://www.marketwatch.com/newsviewer

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

April 15, 2025 06:48 ET (10:48 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2527549693"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2527549693\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2527549693?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-15 18:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2527549693","market":"fut","top_or_hot":-1,"title":"Johnson & Johnson Shares Rise On Q1 Profit And Revenue Beat And Raised Guidance -- MarketWatch","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     Johnson &amp; Johnson <a href=\"https://laohu8.com/S/JNJ\">$(JNJ)$</a> shares rose 0.4% in premarket trades after the medical-technology and drug company beat Wall Street's profit and revenue estimates and raised its full-year sales guidance. \n</p>\n<p>\n     Johnson &amp; Johnson reported per-share earnings of $4.54 for the quarter, which includes the reversal of special charges, up from $1.34 a share in the prior year's quarter. \n</p>\n<p>\n     Adjusted for one-time items, EPS came to $2.77 a share, above the $2.58 FactSet consensus. \n</p>\n<p>\n     Sales rose 2.4% to $21.893 billion, above the FactSet consensus of $21.559 billion. The New Brunswick, N.J.-based company raised its full-year operational sales guidance to a range of $91.6 billion to $92.4 billion, from its prior outlook of $90.9 billion to $91.7 billion. Johnson &amp; Johnson said that this reflects the addition of the CAPLYTA medication for treating bi-polar depression following the completion of the Intra-Cellular Therapies acquisition. \n</p>\n<p>\n     In a separate announcement, Johnson &amp; Johnson announced a 4.8% increase in its quarterly dividend, from $1.24 to $1.30 a share. The raised marked the 63rd year of consecutive dividend raises, the company said. \n</p>\n<p>\n     (This is a developing news story with updates to come.) \n</p>\n<p>\n     -James Rogers \n</p>\n<p>\n  For more from MarketWatch: http://www.marketwatch.com/newsviewer \n</p>\n<p>\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 15, 2025 06:48 ET (10:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson Shares Rise On Q1 Profit And Revenue Beat And Raised Guidance -- MarketWatch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson Shares Rise On Q1 Profit And Revenue Beat And Raised Guidance -- MarketWatch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-15 18:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     Johnson &amp; Johnson <a href=\"https://laohu8.com/S/JNJ\">$(JNJ)$</a> shares rose 0.4% in premarket trades after the medical-technology and drug company beat Wall Street's profit and revenue estimates and raised its full-year sales guidance. \n</p>\n<p>\n     Johnson &amp; Johnson reported per-share earnings of $4.54 for the quarter, which includes the reversal of special charges, up from $1.34 a share in the prior year's quarter. \n</p>\n<p>\n     Adjusted for one-time items, EPS came to $2.77 a share, above the $2.58 FactSet consensus. \n</p>\n<p>\n     Sales rose 2.4% to $21.893 billion, above the FactSet consensus of $21.559 billion. The New Brunswick, N.J.-based company raised its full-year operational sales guidance to a range of $91.6 billion to $92.4 billion, from its prior outlook of $90.9 billion to $91.7 billion. Johnson &amp; Johnson said that this reflects the addition of the CAPLYTA medication for treating bi-polar depression following the completion of the Intra-Cellular Therapies acquisition. \n</p>\n<p>\n     In a separate announcement, Johnson &amp; Johnson announced a 4.8% increase in its quarterly dividend, from $1.24 to $1.30 a share. The raised marked the 63rd year of consecutive dividend raises, the company said. \n</p>\n<p>\n     (This is a developing news story with updates to come.) \n</p>\n<p>\n     -James Rogers \n</p>\n<p>\n  For more from MarketWatch: http://www.marketwatch.com/newsviewer \n</p>\n<p>\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 15, 2025 06:48 ET (10:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JNJ","symbol_name":"强生","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2527549693","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2527549693","pubTimestamp":1744714080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Johnson & Johnson  shares rose 0.4% in premarket trades after the medical-technology and drug company beat Wall Street's profit and revenue estimates and raised its full-year sales guidance.Johnson & Johnson reported per-share earnings of $4.54 for the quarter, which includes the reversal of special charges, up from $1.34 a share in the prior year's quarter.Adjusted for one-time items, EPS came to $2.77 a share, above the $2.58 FactSet consensus.Sales rose 2.4% to $21.893 billion, above the FactSet consensus of $21.559 billion. The New Brunswick, N.J.-based company raised its full-year operational sales guidance to a range of $91.6 billion to $92.4 billion, from its prior outlook of $90.9 billion to $91.7 billion. Johnson & Johnson said that this reflects the addition of the CAPLYTA medication for treating bi-polar depression following the completion of the Intra-Cellular Therapies acquisition.In a separate announcement, Johnson & Johnson announced a 4.8% increase in its quarterly divi","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"JNJ":"强生"},"translate_title":"强生公司股价因第一季度利润和收入超出预期并上调指引而上涨--MarketWatch","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":1},"content_text":"Johnson & Johnson $(JNJ)$ shares rose 0.4% in premarket trades after the medical-technology and drug company beat Wall Street's profit and revenue estimates and raised its full-year sales guidance. \n\n\n     Johnson & Johnson reported per-share earnings of $4.54 for the quarter, which includes the reversal of special charges, up from $1.34 a share in the prior year's quarter. \n\n\n     Adjusted for one-time items, EPS came to $2.77 a share, above the $2.58 FactSet consensus. \n\n\n     Sales rose 2.4% to $21.893 billion, above the FactSet consensus of $21.559 billion. The New Brunswick, N.J.-based company raised its full-year operational sales guidance to a range of $91.6 billion to $92.4 billion, from its prior outlook of $90.9 billion to $91.7 billion. Johnson & Johnson said that this reflects the addition of the CAPLYTA medication for treating bi-polar depression following the completion of the Intra-Cellular Therapies acquisition. \n\n\n     In a separate announcement, Johnson & Johnson announced a 4.8% increase in its quarterly dividend, from $1.24 to $1.30 a share. The raised marked the 63rd year of consecutive dividend raises, the company said. \n\n\n     (This is a developing news story with updates to come.) \n\n\n     -James Rogers \n\n\n  For more from MarketWatch: http://www.marketwatch.com/newsviewer \n\n\n     This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 15, 2025 06:48 ET (10:48 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}